Skip to content

Perspective Therapeutics CATX Goodwill impairment

Goodwill impairment at other companies

Zymeworks logo
ZymeworksZYME
$0

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$28.3M-29.5%
Net income-$26.2M-44.1%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Cash & equivalents$54.0M+21.5%
Total debt$4.2M+10.9%
Total equity$347.4M+22.1%
Total assets$410.8M+24.7%

Cash flow

See full
Operating cash flow-$31.5M-45.8%
CapEx$6.9M+47.3%
Free cash flow-$38.3M-46.1%

Valuation

See full
Market cap$342.14M+33.2%
Enterprise value$292.34M+35.2%
P/S34.2×+19.6×

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp
FCF margin-1,073.3%

Returns & leverage

See full
Return on equity-35.2%+2.3pp
Debt / equity0.0×
Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GoodwillImpairmentLoss.

The official record: Perspective Therapeutics’s 10-K, filed March 16, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's goodwill impairment.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perspective Therapeutics's goodwill impairment?
Perspective Therapeutics (CATX) reported goodwill impairment of $0 in Q4 2025.
How has Perspective Therapeutics's goodwill impairment changed year-over-year?
Perspective Therapeutics's goodwill impairment decreased by 100.0% year-over-year, from $24.1M to $0.
What does goodwill impairment mean?
Write-down of goodwill carrying value when a reporting unit's fair value falls below its book value, indicating that past acquisitions have lost value.